导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.69% | 2715/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -5.31% | 3160/5421 |
| 近一季 | -7.87% | 2558/5209 |
| 近半年 | -3.19% | 2146/4920 |
| 近一年 | 1.90% | 2243/4366 |
| 近两年 | 45.58% | 1622/2954 |
| 近三年 | 29.58% | 1069/2253 |
| 成立以来 | 56.64% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.32% 3133/4961 |
13.33% 2026/5312 |
- - |
- - |
| 2025 | 21.79% 2016/4813 |
-0.06% 2043/3635 |
1.04% 2490/4076 |
20.34% 1993/4524 |
0.22% 2122/4813 |
| 2024 | 16.16% 841/3463 |
2.88% 678/2808 |
-0.92% 872/3014 |
16.24% 1500/3129 |
-1.97% 1905/3463 |
| 2023 | -8.31% 1000/2656 |
4.48% 942/2280 |
-3.89% 952/2385 |
-2.53% 689/2515 |
-6.32% 1717/2655 |
| 2022 | -18.78% 758/2207 |
-12.63% 644/1919 |
6.77% 607/2016 |
-14.00% 1009/2113 |
1.23% 1338/2208 |
| 2021 | -2.67% 866/1822 |
-1.57% 515/1255 |
2.92% 986/1330 |
-5.50% 814/1466 |
1.66% 845/1822 |
| 2020 | 37.21% 382/1250 |
-9.39% 672/1028 |
12.59% 679/1067 |
16.67% 139/1164 |
15.27% 223/1184 |
| 2019 | 37.79% 331/1092 |
23.43% 556/739 |
2.67% 75/788 |
2.01% 334/850 |
6.59% 588/918 |
| 2018 | - - |
- - |
-7.46% 164/631 |
2.17% 117/660 |
-11.61% 328/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方中证A100指数C VS. 长安沪深300非周期A(740101) |